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Introduction: Cardiac resynchronization therapy (CRT) has emerged as an
established therapy for congestive heart failure (CHF). However, up to 30%
of patients fail to respond to CRT despite prolonged QRS and some other
patients respond to CRT despite thin QRS.
The aim of this study was to define the prevalence of mechanical (atrio-
ventricular, interventricular and intraventricular) dissynchrony in heart failure
patients with different QRS durations.
Methods: A total of 46 patients with heart failure (dilated cardiomyopathy
with LVEF < 40%, NYHA II-IV) were prospectively evaluated using 12-lead
electrocardiogram and complete echocardiographic examination including
tissue Doppler imaging. All the patients had sinus rhythm and the dilated car-
diomyopathy was primitive in 37% of patients and ischemic in the others.
Results: According to QRS duration, 16 patients had QRS ≥150ms
(group 1), 15 patients had QRS duration between 120 and 149ms (group 2) and
15 patients had QRS duration < 120ms (group 3). Interventricular dyssynchrony
(IVD) was present in 62% of group 1, 13% of group 2 and was absent in group
3 (p<0,001). Intraventricular dyssynchrony (IntraVD) was present respectively
in 94%, 40%, 20% of groups 1,2, and 3 (p<0,001). However, there was no
significant difference in the prevalence of atrioventricular dyssynchrony (AVD)
between the three groups. A multiparametric approach by focusing on criteria
combination found that the association of IVD + IntraVD + AVD was present
only in group 1 and the combination of two criteria was seen only in group 1
and 2 with a significantly higher prevalence in group 1 (p<0,01).
Conclusion: The prevalence of mechanical dissynchrony increases with
the increasing QRS duration and the combination of criteria is significantly
more prevalent when the QRS width is ≥150ms.
Intraventricular dissynchrony can be observed in heart failure patients with
a narrow QRS complex and may be useful in predicting left ventricular
reverse remodeling after CRT.
The lack of dyssynchrony in some patients with standard CRT indication
by QRS duration may sometimes explain the non responder’s rates.
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Introduction and objectives: Most studies have shown that prognosis of
heart failure with preserved systolic function is as poor as that of heart failure
with depressed systolic function, although these results may be biased by the
fact that these types of heart failure have different characteristics (age,comor-
bidity, treatment), which can influence prognosis. Our aim was to determine
whether short-term morbidity and mortality differed in these 2 subgroups of
heart failure patients when they were comparable in terms of age, associated
comorbidity, and therapy.
Methods: We analyzed 2 groups of patients aged >70 years who were can-
didates to receive beta blockers (preserved systolic function, 145; depressed
systolic function, 174), consecutively discharged from 2 Algerian hospitals
with a diagnosis of heart failure, and compared cardiovascular morbidity and
mortality 3 months after discharge.
Results: Mean age was similar (77.5 vs 78.2 years). Left ventricular ejec-
tion fraction was 56.2%±8.1% vs 33%±6.9% (P<.001). The combined event
rate (death, hospitalization for heart failure, acute coronary syndrome, or
stroke) at 3 months after discharge was lower in patients with heart failure and
preserved systolic function (13.4% vs 20.6%; P=.026). Depressed systolic
function was an independent predictor of greater incidence of events (odds
ratio=1.732; P=.048).
Conclusions: In patients of similar age and receiving similar treatment,
short-term prognosis is better in patients with heart failure and preserved sys-
tolic function than in those with depressed systolic function
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Objective: Analyze the characteristics of heart failure patients with high
doses of loop diuretics and can respond to the notion of resistance to diuretics
Methods: We used the registry hospitalization years 2012 and 2013 the
Department of Medicine, Institute of Cardiology of Abidjan. This was a retro-
spective analysis conducted from 1 January 2012 to 31 December 2013 and
which led to the inclusion 490 patients hospitalized for acute heart failure.
Data on clinical features, ultrasound, biological and therapeutic were collected.
Patients were divided into 3 groups depending on the dose loop diuretics (furose-
mide) to the prescribed output: G1 (Low doses ≤80mg / day, n=124), G2 (inter-
mediate 81-120mg doses / d, n 98), G3 (high doses> 120mg / day, n = 242)
Results: Patients in group G3 distinguished by a clinical picture dominated
by the overall heart failure, a significant impairment of LVEF (90.9% vs
75.8% and 75.5%), the use of inotropic (24% vs 20.9% and 8.2%), a signifi-
cant impairment of renal function at the output (19% vs 17.4% and 10.4),
hyponatremia (42.9% vs 37 1% and 32.6%), higher levels of natriuretic pep-
tides and a longer hospital stay (5.8±3.4 vs 5.5±3 and 5.7±3.1 days). At
decharge, these patients were less frequently an ACE inhibitor or ARA2
(72.7% vs 75.8% and 81.6%) and a beta-blocker (14.8% VS20, 9 and 18.3),
but more frequently mineralocorticoid receptor antagonist. Large doses of
diuretics to the output was associated with increased mortality in two years
Conclusion: The use of high doses of diuretics is associated with a profile
of severe heart failure and a poor prognosis. The diuretic resistance requires
benefit studies to clarify its definition and management
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Introduction: Several studies have shown that unnecessary right ventric-
ular pacing (Vp) has detrimental effects. The ANSWER study evaluated
whether minimization of Vp improves clinical outcome compared to standard
DDD pacing in patients (pts) referred for dual chamber pacemaker implanta-
tion.
Methods: ANSWER is a randomized, long term follow-up, multicenter,
international trial comparing SafeR, a mode designed to minimize Vp by pro-
moting intrinsic conduction, to standard DDD (AV delay left to physician’s
discretion). Pts enrolled suffered from sinus node disease (SND), intermittent
AV block (AVB) or allegedly permanent AVB. All pts were programmed in
SafeR at implant. 1 month after implant, pts were randomized 1:1 to either
SafeR or DDD. All adverse events were blindly adjudicated by a Clinical
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